Advanced Filters
noise

mental-disability Clinical Trials

A listing of mental-disability medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 129 clinical trials
L Laina McAusland, MSc

Pharmacogenetic Supported Prescribing in Kids

Implementation of pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medication.

6 - 24 years of age Both Phase N/A
S Sophia Jan, MD, MSHP

Future Planning and Well-Being for Individuals With Intellectual Disabilities and Family Caregivers

This study will compare the effectiveness of a web-based long-term care planning tool (Map Our Life) partnered with traditional case management services to traditional case management services partnered with an attention-control Centers for Disease Control and Prevention (CDC) sponsored website on health promotion for people with disabilities. The goal of …

18 - 100 years of age Both Phase N/A
S Sophie Durand

Genetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin

Analyze genetic and biological markers in patients with Intellectual Deficiencies (ID) of genetic origin in order to better understand the mechanisms of modified genes, cellular mechanisms, pathways involved in different disorders , complications and pathologies associated with ID of genetic origin.

- 100 years of age Both Phase N/A

Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart Surgery

A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.

70 - 100 years of age Both Phase 4
D David Ziegler, PhD

Enhancing Attention and Wellbeing Using Digital Therapeutics

The goals of the proposed research are to first determine the minimal and/or optimal dose of a digital intervention required for cognitive enhancement, and then to examine the impact of several potential moderators of treatment effects (i.e., cognitive decline, AD polygenic hazard score, cardiovascular risk, and race/ethnicity). This knowledge gained …

60 - 99 years of age Both Phase N/A
T Tiia Ngandu

METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia

Dementia is the main cause of disability in older adults, currently affecting about 50 million people world-wide with this number estimated to triple in the next 30 years. In MET-FINGER, we aim to understand whether the FINGER 2.0 multidomain intervention, combining healthy lifestyle changes and a drug for diabetes (metformin), …

60 - 79 years of age Both Phase 2
J Justin Hunt, MD

Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial

Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and caregivers. We will conduct a clinic-randomized, …

45 - 100 years of age Both Phase N/A
C Coordinator

Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease

The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests. These tests are designed to permit the early detection of individuals at risk of age-related cognitive decline.

18 - 89 years of age Both Phase N/A

Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)

This study is a phase III, prospective, placebo-controlled randomized clinical trial involving 8,518 subjects with low to moderate stroke risk, followed for 3 years in Brazil. Participants will be randomized to receive either the polypill (valsartan 80 mg, amlodipine 5 mg, and rosuvastatin 10 mg), with dose adjustment of amlodipine …

50 - 75 years of age Both Phase 3
E Erin M Peacock, PhD, MPH

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control in Minimize Cognitive Decline

The study will test a multifaceted strategy for implementing an intensive blood pressure intervention protocol targeting systolic BP <120 mmHg on cognitive decline in racial minority and low-income hypertensive patients in primary care. The proposed study will generate urgently needed data on effective, adoptable, and equitable intervention strategies to reduce …

40 - 100 years of age Both Phase N/A

Rewrite in simple language using AI